Tag: renal cell carcinoma

Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial

businessnewstoday- January 29, 2024

Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize treatment for patients with advanced or metastatic ... Read More

Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial

businessnewstoday- January 29, 2024

Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564 trial. This pivotal study demonstrates that KEYTRUDA, ... Read More

Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial

businessnewstoday- August 20, 2023

Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical milestone in its Phase 3 trial LITESPARK-005. ... Read More

LG Chem to acquire US biotech company Aveo Oncology for $566m

Raghuram Kadari- October 18, 2022

LG Chem acquisition of Aveo Oncology : South Korea’s LG Chem has entered into a definitive agreement to acquire Aveo Oncology, a US-based biotech company, ... Read More

US FDA approves Opdivo, Cabometyx combo for advanced renal cell carcinoma

pharmanewsdaily- January 26, 2021

The US Food and Drug Administration (FDA) has approved the combination of Bristol Myers Squibb’ Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib) as a first line ... Read More

Merck to acquire US biopharma company Peloton Therapeutics in $2.2bn deal

pharmanewsdaily- July 14, 2019

Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, ... Read More